ranibizumab   Click here for help

GtoPdb Ligand ID: 6779

Synonyms: Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
Approved drug
ranibizumab is an approved drug (FDA (2006), EMA (2007))
Compound class: Antibody
Comment: Ranibizumab is a Fab fragment of a monoclonal antibody designed to target vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody derivative are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that ranibizumab sequences are claimed in patent WO1998045331 (clone Y0317) [2], with an expected affinity similar to clone Y0313-1. It is the Fab fragment of bevacizumab.

Name(s)Trade nameCompanyClinical PhaseIndications
Razumab®Intas PharmaceuticalsApproved (India 2015)As per reference agent
SB11; ranibizumab-nunaByooviz®Samsung BioepisApproved (EMA & FDA 2021)As per reference agent
Susvimo®Genentech/RocheApproved (FDA 2021)wet AMD
FYB201; ranibizumab-eqrnCimerli®Coherus BioSciencesApproved (FDA 2022)As per reference agent
Ranivisio®Midas PharmaApproved (EMA 2022)wet AMD
Ximluci®STADA ArzneimittelApproved (EMA 2022)As per reference agent
No information available.
Summary of Clinical Use Click here for help
Used to treat macular edema after retinal vein occlusion, age-related (wet) macular degeneration, and diabetic macular edema. Administered by intravitreal injection.
In February 2015, the US FDA expanded approval to include treatment of diabetic retinopathy. FDA approval was further expaned to include myopic choroidal neovascularization (mCNV; a complication of severe near-sightedness that can lead to blindness) in January 2017.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Binds to and inhibits the biologic activity (neo-vascularisation/vessel permeabiity) of active forms of human vascular endothelial growth factor A [3].
External links Click here for help